ALNY · XBRL financial data

Alnylam Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ALNY's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue from contracts with customers	751	440*	494	660	501	593*	594	774	1,249	1,097*	1,291	1,458
Cost of goods and services sold	79	72*	55	67	82	103*	70	142	197	268*	298	362
Research and development	253	272*	261	294	271	300*	265	324	359	372*	413	409
Selling, general and administrative	199	198*	211	248	221	295*	240	323	322	325*	348	342
Operating income (loss)	214	(116)*	(43)	49	(77)	(105)*	18	(16)	368	132*	231	346
Interest income	25	30*	30	29	32	31*	29	27	29	27*	28	31
Interest expense	31	31*	35	33	34	39*	39	40	44	129*	82	84
Other income (expense)	(58)	(20)*	(15)	(56)	(30)	(81)*	(50)	(6)	(74)	135*	0	3
Income tax expense (benefit)	3	0*	2	6	3	(110)*	16	31	(12)	(25)*	13	(1,872)
Net income (loss)	148	(138)*	(66)	(17)	(112)	(84)*	(57)	(66)	251	186*	164	2,167
Earnings per share, basic USD per share	1.18	(1.10)*	(0.52)	(0.13)	(0.87)	(0.65)*	(0.44)	(0.51)	1.91	1.41*	1.23	16.19
Earnings per share, diluted USD per share	1.15	(1.15)*	(0.52)	(0.13)	(0.87)	(0.65)*	(0.44)	(0.51)	1.84	—	1.21	15.72
Weighted average shares, basic millions of shares	125	126*	126	127	129	129*	130	131	131	132*	134	134
Weighted average shares, diluted millions of shares	131	119*	126	127	129	129*	130	131	137	141*	138	138

Balance sheet

CSV

Fiscal quarters (ALNY's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	1,033	813	682	968	1,100	966	1,020	1,114	1,490	1,657	1,708	1,754
Marketable securities	1,363	1,616	1,678	1,646	1,672	1,720	1,605	1,744	1,234	1,251	1,600	1,833
Accounts receivable	325	328	321	309	354	405	418	567	965	778	913	1,085
Inventory	96	89	94	84	76	79	66	72	75	83	97	106
Prepaid and other current assets	158	126	202	155	145	117	152	147	188	282	302	335
Total current assets	2,985	2,983	2,989	3,173	3,355	3,295	3,268	3,644	3,953	4,051	4,620	5,113
Property and equipment, net	526	526	523	517	507	503	499	500	502	513	554	615
Right-of-use asset	203	200	195	198	196	191	197	192	191	195	183	178
Total assets	3,839	3,830	3,824	4,010	4,205	4,240	4,214	4,566	4,852	4,966	5,559	7,995
Accounts payable	74	56	78	74	71	88	97	102	118	116	108	135
Accrued liabilities	713	713	699	809	946	887	704	919	1,154	1,080	1,096	1,236
Total current liabilities	950	968	942	1,055	1,221	1,186	1,076	1,301	1,555	1,466	1,513	2,063
Lease liability, non-current	248	243	238	239	236	230	230	224	223	225	210	203
Total liabilities	4,005	4,051	4,044	4,013	4,173	4,173	4,098	4,315	4,618	4,177	4,205	4,391
Accumulated deficit	(6,872)	(7,010)	(7,076)	(7,092)	(7,204)	(7,288)	(7,345)	(7,412)	(7,160)	(6,703)	(6,332)	(4,165)
Total stockholders' equity	(166)	(221)	(219)	(3)	32	67	115	251	234	789	1,354	3,604
Total liabilities and equity	3,839	3,830	3,824	4,010	4,205	4,240	4,214	4,566	4,852	4,966	5,559	7,995
Common shares outstanding (cover page) millions of shares	125	126	126	128	129	129	130	131	132	133	134	134

Cash flows

CSV

Fiscal quarters (ALNY's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	148	(138)*	(66)	(17)	(112)	(84)*	(57)	(66)	251	186*	164	2,167
Stock-based compensation	64*	42*	45	89*	46*	92*	57	112*	108*	72*	—	79*
Net cash from operating activities	359*	(30)*	(82)	124*	44*	(95)*	(118)	154*	325*	164*	—	341*
Purchases of property and equipment	17*	15*	13	8*	4*	9*	9	14*	12*	23*	—	70*
Net cash from investing activities	(11)*	(241)*	(68)	34*	(30)*	(53)*	114	(141)*	501*	(37)*	—	(312)*
Net cash from financing activities	33*	39*	29	131*	103*	31*	44	54*	(448)*	45*	—	18*
Net change in cash	375*	(220)*	(130)	286*	131*	(134)*	54	94*	377*	166*	—	46*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Quarter
Alnylam Pharmaceuticals	1,754	1,458	341*	133.9M	Q3 FY26 10-QSep 30, 2026
Idexx Laboratories	198	1,214	450*	78.8M	Q3 FY26 10-QSep 30, 2026
Regeneron Pharmaceuticals	3,659	5,116	1,783*	not reported	Q3 FY26 10-QSep 30, 2026
Zoetis	1,476	2,468	655*	413.2M	Q2 FY26 10-QJun 30, 2026
INSMED	397	524	(36)*	219.4M	Q3 FY26 10-QSep 30, 2026
Bristol Myers Squibb	9,574	13,069	4,181*	2.0B	Q3 FY26 10-QSep 30, 2026
Biogen	1,304	2,804	641*	147.8M	Q3 FY26 10-QSep 30, 2026
Teva Pharmaceutical Industries	4,085	4,395	241	1.2B	Q3 FY26 10-QSep 30, 2026
Gilead Sciences	6,437	8,300	5,035*	1.2B	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.